Leerink Partners Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock

Protagonist Therapeutics (NASDAQ:PTGX) had its target price lifted by investment analysts at Leerink Partners from $107.00 to $110.00 in a report released on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Leerink Partners’ price objective suggests a potential upside of 11.26% from the stock’s previous close.

Several other analysts have also commented on the stock. Barclays increased their price target on shares of Protagonist Therapeutics from $113.00 to $119.00 and gave the company an “overweight” rating in a research report on Thursday. HC Wainwright lifted their price objective on Protagonist Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Johnson Rice reaffirmed a “buy” rating on shares of Protagonist Therapeutics in a research note on Wednesday. TD Cowen raised their price target on Protagonist Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, JPMorgan Chase & Co. boosted their price target on Protagonist Therapeutics from $95.00 to $106.00 and gave the stock an “overweight” rating in a report on Thursday. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Protagonist Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $107.31.

Protagonist Therapeutics Trading Down 2.8%

Shares of NASDAQ PTGX opened at $98.87 on Thursday. The company’s 50-day moving average price is $87.17 and its 200 day moving average price is $80.87. Protagonist Therapeutics has a 52 week low of $39.60 and a 52 week high of $105.69. The stock has a market cap of $6.31 billion, a price-to-earnings ratio of -48.23 and a beta of 2.23.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.16). Protagonist Therapeutics had a negative return on equity of 19.89% and a negative net margin of 282.83%.The business had revenue of $7.44 million for the quarter, compared to analyst estimates of $14.92 million. As a group, research analysts expect that Protagonist Therapeutics will post 2.43 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director William D. Waddill sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $83.68, for a total transaction of $1,673,600.00. Following the transaction, the director owned 7,825 shares of the company’s stock, valued at approximately $654,796. This represents a 71.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Dinesh V. Ph D. Patel sold 34,438 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $82.48, for a total transaction of $2,840,446.24. Following the sale, the chief executive officer owned 580,505 shares in the company, valued at approximately $47,880,052.40. This trade represents a 5.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 203,167 shares of company stock valued at $16,889,199. 4.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Protagonist Therapeutics

Several hedge funds have recently made changes to their positions in the business. Rockefeller Capital Management L.P. boosted its holdings in shares of Protagonist Therapeutics by 10.5% during the fourth quarter. Rockefeller Capital Management L.P. now owns 3,292 shares of the company’s stock worth $288,000 after purchasing an additional 312 shares during the last quarter. Seven Fleet Capital Management LP acquired a new position in Protagonist Therapeutics in the fourth quarter valued at $699,000. Invesco Ltd. increased its stake in Protagonist Therapeutics by 56.2% in the fourth quarter. Invesco Ltd. now owns 1,567,840 shares of the company’s stock valued at $136,935,000 after purchasing an additional 564,134 shares during the last quarter. KVP Capital Advisors LP purchased a new position in Protagonist Therapeutics during the fourth quarter worth about $4,629,000. Finally, Virtus Investment Advisers LLC lifted its position in Protagonist Therapeutics by 38.1% during the fourth quarter. Virtus Investment Advisers LLC now owns 2,790 shares of the company’s stock worth $244,000 after buying an additional 770 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics News Roundup

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: FDA approval of J&J’s Icotyde for plaque psoriasis materially improves Protagonist’s near-term commercial outlook by triggering milestone payments and future royalty upside tied to Protagonist’s partnered program. Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here’s Why
• Positive Sentiment: Market reaction: coverage highlights a ~6–7% lift tied to the approval and notes the path to royalties; higher-than-average volume suggests institutional interest and re-rating momentum. Why Protagonist Therapeutics (PTGX) Is Up 6.6% After First Psoriasis Drug Wins FDA Approval
• Positive Sentiment: Several major banks raised price targets and reiterated buy/overweight ratings following the approval, providing further upside expectations (Leerink, JPMorgan, Citigroup, Barclays). These analyst upgrades are supporting the stock’s recent run. Analyst coverage roundup (Benzinga) JPMorgan note (TickerReport) Citigroup coverage (Zacks)
• Positive Sentiment: Zacks notes recent momentum and that recent earnings-estimate revisions could support further upside in the near term. Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
• Neutral Sentiment: Broader Wall Street commentary emphasizes that J&J’s approval should create “significant value” for Protagonist, reinforcing sentiment but not guaranteeing cash flow until milestones/royalties are realized. Wall Street says J&J’s FDA-approved psoriasis drug should create significant value for Protagonist
• Negative Sentiment: Key risk: Protagonist reported an earnings and revenue miss in its last report and remains unprofitable with negative margins—meaning the market is pricing future milestone/royalty potential rather than current cash generation. This raises execution and timing risk (milestones may be delayed or smaller than expected).

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.